We further hypothesize that an exogenously constructed, irreversible and stable CRP mutant capable of binding to factor H should be able to protect mice against late-stage infection; such a CRP molecule when administered into mice would bind to factor H on pneumococci in vivo and mask the complement inhibitory activity of factor H (48). Here, CRP is linked to infection.